Cargando…
A(2A) blockade enhances anti-metastatic immune responses
The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A(2A)/A(2B) adenosine receptors significantly reduced...
Autores principales: | Beavis, Paul A, Milenkovski, Nicole, Stagg, John, Smyth, Mark J, Darcy, Phillip K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926871/ https://www.ncbi.nlm.nih.gov/pubmed/24575377 http://dx.doi.org/10.4161/onci.26705 |
Ejemplares similares
-
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013) -
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014) -
Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014) -
The double-edge sword effect of anti-CD73 cancer therapy
por: Stagg, John
Publicado: (2012) -
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)